January 2004 - Volume 14 - Issue 1
pp: 1-71
Subscribe to eTOC


The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

Visser, Loes E; van Vliet, Martin; van Schaik, Ron HN; More

Pharmacogenetics . 14(1):27-33, January 2004.

Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor therapy in men

Maitland-van der Zee, Anke Hilse; Klungel, Olaf H; Stricker, Bruno HCh; More

Pharmacogenetics . 14(1):53-60, January 2004.